Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy-Reference-Cited by-同舟云学术

Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy

Published:2023-09 Issue: Volume:36 Page:100981
ISSN:2214-4269
Container-title:Molecular Genetics and Metabolism Reports
language:en
Short-container-title:Molecular Genetics and Metabolism Reports

Author:

Kim Katherine H.,Desai Ankit K.,Vucko Erika R.,Boggs Tracy,Kishnani Priya S.,Burton Barbara K.

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology

Reference22 articles.

1. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease;Case;Neuromuscul. Disord.,2015

2. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open label single-center study;van Gelder;J. Inherit. Metab. Dis.,2016

3. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature;Khan;Genet. Med.,2020

4. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy;Katzin;J. Clin. Neuromuscul. Dis.,2008

5. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants;Kishnani;Mol. Genet. Metab.,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy;Frontiers in Immunology;2024-04-23

2. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation;Frontiers in Immunology;2024-03-08

3. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa;Frontiers in Genetics;2024-01-19